Crawling Stone Consulting — Translating discovery into clinical reality

Publications and presentations

Peer-reviewed work on inducible costimulation in CAR-T cells, B cell receptor and BAFF receptor signaling, and Epstein-Barr virus biology, together with invited presentations and conference abstracts on CAR-T control and TIL process validation.

Peer-reviewed publications

Thirteen articles and chapters, 2002 to 2019.

  1. Collinson-Pautz MR, Chang WC, Lu A, Khalil M, Crisostomo JW, Lin PY, Mahendravada A, Shinners NP, Brandt ME, Zhang M, Duong M, Bayle JH, Slawin KM, Spencer D, Foster AE. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia. 2019;33(9):2195-2207.
  2. Foster AE, Mahendravada A, Shinners NP, Chang WC, Crisostomo J, Lu A, Khalil M, Morschl E, Shaw J, Saha S, Duong MT, Collinson-Pautz MR, Torres M, Rodriguez T, Pentcheva-Hoang T, Bayle JH, Slawin KM, Spencer DM. Regulated expansion and survival of chimeric antigen receptor-modified T cells using small molecule-dependent inducible MyD88/CD40. Mol Ther. 2017;25(9):2176-2188.
  3. Havranek O, Xu J, Kohrer S, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Ma JMC, Westin JR, Ghosh D, Shinners NP, Sun L, Yi AF, Karri AR, Burger JA, Zal T, Davis RE. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood. 2017;130(8):995-1006.
  4. Gewurz BE, Towfic F, Mar JC, Shinners NP, Takasaki K, Zhao B, Cahir-McFarland ED, Quackenbush J, Xavier RJ, Kieff E. Genome-wide siRNA screen for mediators of NF-κB activation. PNAS. 2012;109(7):2467-2472.
  5. Gewurz BE, Mar JC, Padi M, Zhao B, Shinners NP, Takasaki K, Bedoya E, Zou JY, Cahir-McFarland E, Quackenbush J, Kieff E. Canonical NF-κB activation is essential for Epstein-Barr virus latent membrane protein 1 TES2/CTAR2 gene regulation. J Virol. 2011;85(13):6764-6773.
  6. Khan WN, Shinners NP, Castro I, Hoek KL. BAFF receptor regulation of peripheral B-lymphocyte survival and development. In: Cancro MP, ed. BLyS Ligands and Receptors. New York, NY: Humana Press; 2010:19-41.
  7. Castro I, Wright JA, Damdinsuren B, Hoek KL, Carlesso G, Shinners NP, Gerstein RM, Woodland RT, Sen R, Khan WN. B cell receptor-mediated sustained c-Rel activation facilitates late transitional B cell survival through control of B cell activating factor receptor and NF-κB2. J Immunol. 2009;182(12):7729-7737.
  8. Song YJ, Izumi KM, Shinners NP, Gewurz BE, Kieff E. IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, not TRAF2 or TRAF3. PNAS. 2008;105(47):18448-18453.
  9. Shinners NP, Carlesso G, Castro I, Hoek KL, Corn RA, Woodland RT, Scott ML, Wang D, Khan WN. Bruton's tyrosine kinase mediates NF-κB activation and B cell survival by B cell activating factor of the TNF family. J Immunol. 2007;179(6):3872-3880.
  10. Hoek KL, Antony P, Lowe J, Sarmah B, Shinners NP, Wente SR, Wang D, Gerstein RM, Khan WN. Transitional B cell fate is associated with developmental stage-specific regulation of diacylglycerol and calcium signalling upon BCR engagement. J Immunol. 2006;177(8):5405-5413.
  11. Antony P, Petro JB, Carlesso G, Shinners NP, Lowe J, Khan WN. B-cell antigen receptor activates transcription factors NFAT and NF-κB via a mechanism that involves diacylglycerol. Biochem Soc Trans. 2004;32(Pt 1):113-115.
  12. Antony P, Petro JB, Carlesso G, Shinners NP, Lowe J, Khan WN. B cell receptor directs the activation of NFAT and NF-κB via distinct molecular mechanisms. Exp Cell Res. 2003;291:11-24.
  13. Petro JB, Gerstein RM, Lowe J, Carter RS, Shinners N, Khan WN. Transitional type 1 and 2 B lymphocyte subsets are differentially responsive to antigen receptor signaling. J Biol Chem. 2002;277:48009-48019.

Invited presentations

  1. Controlling CAR-T cell function in vivo using molecular switches. Adoptive T Cell Congress, London, UK, 2016.
  2. Controlling CAR-T cell function in vivo using molecular switches. Cambridge Healthtech Institute Cancer Biotherapeutics, London, UK, 2016.

Abstracts and posters

SITC, ASH, ASCO, AAI, and Keystone, 2005 to 2022.

Published abstracts and posters (14)
  1. Murthy P, Narasappa N, Liang X, Wu X, Luu I, Jeevan J, Sharma S, Ross A, Lampenfeld C, Zahn S, Musial T, Bone J, Nakayama J, Bartlett DL, Chapman JS, Garrido G, Shinners N, Sands AT, Blackton M, Wang E, Lotze MT. Universal expansion of CBL-B-inhibited tumor-infiltrating lymphocytes, DeTIL-0255, from women with ovarian cancer: process validation. SITC, Boston, MA, 2022.
  2. Foster A, Lin PY, Lu A, Chang WC, Shinners N, Khalil M, Crisostomo J, Mahendravada A, Slawin K, Spencer D. MyD88/CD40 enhanced CD19-specific CAR-T cells maintain therapeutic efficacy following resolution of cytokine-related toxicity using inducible caspase-9. American Society of Hematology Annual Meeting, Atlanta, GA, 2017.
  3. Mackay S, Flynn B, Morse K, Ng C, Gallatin K, Paczkowski P, Mahendravada A, Shinners N, Spencer D, Foster A, Zhou J. Single-cell multiplex proteomics reveals synergistic impact of antigen and rimiducid-dependent stimulatory signals on promoting polyfunctional GoCAR-T cells targeting prostate stem cell antigen (PSCA). American Society of Hematology Annual Meeting, Atlanta, GA, 2017.
  4. Foster A, Duong M, Lu A, Chang P, Mahendravada A, Shinners N, Slawin K, Bayle J, Spencer D. Inducible MyD88/CD40 (iMC) costimulation provides ligand-dependent tumor eradication by CD123-specific chimeric antigen receptor T cells. American Society of Hematology Annual Meeting, San Diego, CA, 2016.
  5. Slawin KM, Mahendravada A, Shinners N, Chang P, Lu A, Crisostomo J, Morschl E, Shaw J, Saha S, Spencer DM, Foster AE. Inducible MyD88/CD40 allows rimiducid-dependent activation to control proliferation and survival of chimeric antigen receptor (CAR) T cells targeting prostate stem cell antigen (PSCA). ASCO Genitourinary Cancers Symposium, San Francisco, CA, 2016.
  6. Foster A, Mahendravada A, Shinners N, et al. Inducible MyD88/CD40 allows rimiducid-dependent activation to control proliferation and survival of chimeric antigen receptor-modified T cells. American Society of Hematology Annual Meeting, Orlando, FL, 2015.
  7. Foster A, et al. Controlling CAR-T cell function in vivo using molecular switches. CAR-T Summit, Boston, MA, 2015.
  8. Foster A, Mahendravada A, Chang P, Shinners N, Lu A, Saha S, Slawin K, Spencer DM. Inducible MyD88/CD40 allows AP1903-dependent costimulation to control proliferation and survival of chimeric antigen receptor-modified T cells. American Society of Hematology Annual Meeting, San Francisco, CA, 2014.
  9. Havranek O, Ghosh D, Shinners NP, Wang Z, Xu J, Sun L, Ma W, Davis RE. The B-cell receptor is required for optimal viability, growth, and chemotherapy resistance of diffuse large B-cell lymphoma cell lines of the germinal center B-cell subtype. ASH Meeting on Lymphoma Biology, Colorado Springs, CO, 2014.
  10. Shinners NP, Ma W, Liang H, Gao Y, Davis RE. A "missing finger" method for effective zinc finger nuclease design and construction. Innovations in Cancer Prevention and Research Conference, Austin, TX, 2011.
  11. Song Y, Izumi K, Shinners NP, Kieff ED. TES2-mediated signaling and binding to IRF7 are essential for EBV LMP1-induced IRF7 activation. International Herpes Workshop, Estoril, Portugal, 2008.
  12. Shinners NP, Carlesso G, Castro I, Antony P, Khan WN. BAFF activates classical NF-κB pathway via a Btk-dependent mechanism to regulate alternative NF-κB pathway and B cell survival. AAI Meeting, Boston, MA, 2006.
  13. Shinners NP, Castro I, Antony P, Hoek K, Carlesso G, Llanes J, Khan WN. Btk couples BAFF-R to classical NF-κB pathway and anti-apoptotic genes. Keystone Meeting, Denver, CO, 2005.
  14. Carlesso G, Hoek KL, Shinners NP, Wang D, Rao SP, Khan WN. B cell antigen receptor and Toll-like receptor-4 converge on NF-κB to regulate BAFF-R expression. Keystone Meeting, Denver, CO, 2005.

Begin with a program, a question, or a portfolio.

Most engagements begin with a short call to establish where the program stands and which decision comes next, whether it concerns regulatory strategy, manufacturing, nonclinical development, clinical readiness, intellectual property, or the disposition of a portfolio.

Start a conversation